SE501592C2 - Antivirus- och antitumörkomposition innefattande ett antivirus- och antitumörxantat och en jonisk adjuvantförening - Google Patents

Antivirus- och antitumörkomposition innefattande ett antivirus- och antitumörxantat och en jonisk adjuvantförening

Info

Publication number
SE501592C2
SE501592C2 SE8603284A SE8603284A SE501592C2 SE 501592 C2 SE501592 C2 SE 501592C2 SE 8603284 A SE8603284 A SE 8603284A SE 8603284 A SE8603284 A SE 8603284A SE 501592 C2 SE501592 C2 SE 501592C2
Authority
SE
Sweden
Prior art keywords
acid
xanthate
sodium
potassium
antiviral
Prior art date
Application number
SE8603284A
Other languages
English (en)
Swedish (sv)
Other versions
SE8603284D0 (sv
SE8603284L (sv
Inventor
Gerhard Sauer
Eberhard Amtmann
Klaus W Hummel
Original Assignee
Ct Holding Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Holding Sa filed Critical Ct Holding Sa
Publication of SE8603284D0 publication Critical patent/SE8603284D0/xx
Publication of SE8603284L publication Critical patent/SE8603284L/xx
Publication of SE501592C2 publication Critical patent/SE501592C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE8603284A 1985-08-02 1986-08-01 Antivirus- och antitumörkomposition innefattande ett antivirus- och antitumörxantat och en jonisk adjuvantförening SE501592C2 (sv)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE3527871 1985-08-02
DE3620939 1986-06-23

Publications (3)

Publication Number Publication Date
SE8603284D0 SE8603284D0 (sv) 1986-08-01
SE8603284L SE8603284L (sv) 1987-02-03
SE501592C2 true SE501592C2 (sv) 1995-03-20

Family

ID=25834701

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8603284A SE501592C2 (sv) 1985-08-02 1986-08-01 Antivirus- och antitumörkomposition innefattande ett antivirus- och antitumörxantat och en jonisk adjuvantförening

Country Status (14)

Country Link
US (1) US4851435A (it)
JP (1) JPH0618786B2 (it)
AU (1) AU585380B2 (it)
BE (1) BE905195A (it)
CA (1) CA1295944C (it)
CH (1) CH673224A5 (it)
DK (1) DK369186A (it)
FR (1) FR2591483B1 (it)
GB (1) GB2178957B (it)
GR (1) GR862030B (it)
IT (1) IT1213453B (it)
LU (1) LU86533A1 (it)
NL (1) NL8601895A (it)
SE (1) SE501592C2 (it)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT392906B (de) * 1987-10-08 1991-07-10 Hoffmann La Roche Pharmazeutische praeparate zur oralen verabreichung
CA2010511A1 (en) * 1989-03-01 1990-09-01 Roberto L. Ceriani Method of enhancing cancer therapy by administration of unsaturated fatty acids
WO1996014841A1 (en) * 1994-11-14 1996-05-23 Ct-Holding S.A. Antiviral and antitumor pharmaceutical compositions
DE10117728A1 (de) * 2001-04-09 2002-10-17 Biosphings Ag Pharmazeutische Formulierungen für Xanthogenate
DE10156617A1 (de) * 2001-11-17 2003-05-28 Biosphings Ag Herstellung reiner Stereoisomere von Tricyclo[5.2.1.0··2··.··6··]-dec-9-yl-xanthogenat und Arzneimittel daraus
DE10343365A1 (de) * 2003-09-17 2005-04-14 Biosphings Ag Pharmazeutische Formulierungen von Xanthogenaten und Hemmstoffen der viralen Nukleinsäurereplikation
EP2422789B1 (en) * 2004-05-19 2017-11-22 Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center Injectable coposition comprising sodium deoxycholate
US7754230B2 (en) * 2004-05-19 2010-07-13 The Regents Of The University Of California Methods and related compositions for reduction of fat
US20060127468A1 (en) 2004-05-19 2006-06-15 Kolodney Michael S Methods and related compositions for reduction of fat and skin tightening
DE102006014390A1 (de) * 2006-03-29 2007-10-04 Biosphings Ag Assoziate von Xanthogenaten mit Cyclodextrinen und ihre Verwendung
CN101796024A (zh) * 2007-07-03 2010-08-04 露马维塔股份公司 三环癸-9-基-黄原酸酯的立体异构体
US8101593B2 (en) 2009-03-03 2012-01-24 Kythera Biopharmaceuticals, Inc. Formulations of deoxycholic acid and salts thereof
MX363465B (es) 2011-02-18 2019-03-25 Kythera Biopharmaceuticals Inc Tratamiento de la grasa submental.
US8653058B2 (en) 2011-04-05 2014-02-18 Kythera Biopharmaceuticals, Inc. Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4020183A (en) * 1974-12-03 1977-04-26 Ortho Pharmaceutical Corporation Nonionic surface active anti-herpes simplex viral agents
KR870001238B1 (ko) * 1980-11-26 1987-06-26 메르츠+캄패니 게엠베하 앤드 캄패니 크산틴산염의 제조방법
CA1174978A (en) * 1980-11-26 1984-09-25 Arthur Scherm Xanthates
DK315482A (da) * 1981-07-20 1983-01-21 Kimberly Clark Co Fremgangsmaade til hindring af spredning af aandedraetsvira og middel til anvendelse ved fremgangsmaaden

Also Published As

Publication number Publication date
GB8618820D0 (en) 1986-09-10
BE905195A (fr) 1987-01-29
SE8603284D0 (sv) 1986-08-01
GR862030B (en) 1986-12-24
JPH0618786B2 (ja) 1994-03-16
FR2591483A1 (fr) 1987-06-19
JPS6259223A (ja) 1987-03-14
AU6064886A (en) 1987-02-05
GB2178957B (en) 1989-12-28
DK369186D0 (da) 1986-08-01
CA1295944C (en) 1992-02-18
CH673224A5 (it) 1990-02-28
DK369186A (da) 1987-02-03
IT8621192A0 (it) 1986-07-21
NL8601895A (nl) 1987-03-02
FR2591483B1 (fr) 1990-08-10
AU585380B2 (en) 1989-06-15
IT1213453B (it) 1989-12-20
US4851435A (en) 1989-07-25
SE8603284L (sv) 1987-02-03
LU86533A1 (fr) 1988-02-02
GB2178957A (en) 1987-02-25

Similar Documents

Publication Publication Date Title
SE501592C2 (sv) Antivirus- och antitumörkomposition innefattande ett antivirus- och antitumörxantat och en jonisk adjuvantförening
CN114191553B (zh) 抗新型冠状病毒SARS-CoV-2的药物及其应用
AU608824B2 (en) Agent for the prophylaxis and therapy of retroviral infections
Huleihel et al. Antiviral effect of red microalgal polysaccharides on Herpes simplex and Varicella zoster viruses
Jackson Jr et al. Cytotoxic thresholds of vincristine in a murine and a human leukemia cell line in vitro
EP0975366A1 (en) Cytoprotective agents comprising monoamine oxidase inhibitors
US5491135A (en) Compositions of N-(phosphonoacetyl)-L-aspartic acid and methods of their use as broad spectrum antivirals
AU617115B2 (en) A pharmaceutical combination product and the preparation and use thereof
Soike et al. Acyclovir treatment of experimental simian varicella infection of monkeys
McGRATH et al. Effects of GLQ223™ on HIV Replication in Human Monocyte/Macrophages Chronically Infected In Vitro with HIV
JP3250804B2 (ja) 治療用ペプチド
KR960000432B1 (ko) 제약학적 생성물
EP0610444B1 (en) Use of a polyhydroxybenzamide or a derivative thereof in the manufacture of a medicament for treating viral infectious diseases
Collins et al. Comparison of activity of herpes virus inhibitors
Pouillart et al. Enhancement by stable butyrate derivatives of antitumor and antiviral actions of interferon
O'Brien et al. Assessment of antiviral activity, efficacy, and toxicity of prostaglandin A2 in a rabbit model of herpetic keratitis
Hoover et al. Feline leukemia virus-induced immunodeficiency syndrome in cats as a model for evaluation of antiretroviral therapy
RU2316320C1 (ru) Противовирусное средство
US3859433A (en) Antiviral treatment
KR100718030B1 (ko) 변형성 관절증 치료제
US9351960B2 (en) Agent for the treatment of viral hepatitis C
RU2001917C1 (ru) Способ лечени патологических состо ний, сопровождающихс нехваткой GT РНК
CS275793B6 (en) Production method of the antivirus and antitumour agent
US4822783A (en) Method for treating HTLV-I using streptovaricin C compounds
Bucknall Why aren't antivirals effective when administered intranasally?